Mail Label No. Dated:

Docket No.: 04280/100M321-US1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Alan J. Korman

Application No.: 09/644,668

Filed: August 24, 2000

HUMAN CTLA-4 ANTIBODIES AND For:

THEIR USES

Confirmation No.:

Art Unit: 1644

Examiner: J. H. Roark

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark . Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "Documents Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

A copy of each document on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as 2 Docket No.: 04280/100M321-US1

Application No.: 09/644,668

defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed documents.

Our check in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: February 24, 2004

Respectfully submitted.

Paul M. Zagar, M.D

Registration No. 52,392 DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicant

TAMpplication No. (if known): 09/644,668

Attorney Docket No.: 04280/100M321-US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to:

EL983946638W

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

on 2/24/04

Typed of printed name of person signing Certificate


Note:

Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Supplemental IDS (2 pgs) Form PTO SB-08 (3 pgs)

75 Documents

Check No. 4240 for \$180.00.



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known			
Application Number	09/644,668		
Filing Date	August 24, 2000		
First Named Inventor	Alan J. Korman		
Art Unit	1644		
Examiner Name	J. H. Roark		
Attorney Docket Number	04280/100M321-US1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-6,682,736-B1	01-27-2004	Hanson et al.	
	2	US-5,648,471-B1	07-15-1997	Buttram et al.	
	3	US-4,399,216-B1	08-16-1983	Axel et al.	-
	4	US-4,681,581-B1	07-21-1987	Coates	
	5	US-4,683,195-B1	07-28-1987	Mullis et al.	
	6	US-4,683,202-B1	07-28-1987	Mullis	
	7	US-4,735,210-B1	04-05-1988	Goldenberg	
	8	US-4,740,461-B1	04-26-1988	Kaufman	
	9	US-4,816,397-B1	03-28-1989	Boss et al.	-
	10	US-4,921,040-B1	05-01-1990	Ueruenduel et al.	
	11	US-4,959,455-B1	09-25-1990	Clark et al.	
	12	US-5,101,827-B1	04-07-1992		
	13	US-5,151,510-B1	09-29-1992	Stec et al.	
	14	US-5,194,594-B1	03-16-1993	Khawli et al.	
	15	US-5,434,131-B1	07-18-1995	Linsley et al.	
	16	US-5,530,101-B1	06-25-1996	Queen et al.	
	17	US-5,545,807-B1	08-13-1996	Surani et al.	
	18	US-5,585,089-B1	12-17-1996	Queen et al.	
	19	US-5,591,669-B1	01-07-1997	Krimpenfort et al.	
	20	US-5,612,205-B1	03-18-1997	Kay et al.	
	21	US-RE 35,500-B1	05-06-1997	Rhodes	
	22	US-5,643,763-B1	07-01-1997	Dunn et al.	
	23	US-5,693,761-B1	12-02-1997	Queen et al.	
	24	US-5,693,792-B1	12-02-1997	Torii et al.	
	25	US-5,697,902-B1	12-16-1997	Goldenberg	
	26	US-5,703,057-B1	12-30-1997	Johnston et al.	
	27	US-5,714,350-B1	02-03-1998	Co et al.	
	28	US-5,721,367-B1	02-24-1998	Kay et al.	
	29	US-5,733,743-B1	03-31-1998		
	30	US-5,741,957-B1	04-21-1998	Deboer et al.	
	31	US-5,750,172-B1	05-12-1998	Meade et al.	
	32	US-5,756,687-B1	05-26-1998	Denman et al.	
	33	US-5,773,253-B1		Linsley et al.	
	34	US-5,777,085-B1	07-07-1998		
	35	US-5,789,215-B1	08-04-1998	Berns et al.	
	36	US-5,827,690-B1	10-27-1998	Meade et al.	
	37	US-5,916,771-B1	06-29-1999	Hori et al.	
	38	US-6,051,227-B1	04-18-2000	Allison et al.	
	39	US-6,207,156-B1	03-27-2001	Kuchroo et al.	
	40	US-6,255,458-B1	07-03-2001	Lonberg et al.	
	41	US-2002/0086014-A1	04-04-2002	Korman et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	™

Examiner	Date	
Signature	Considere	d

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known				
Application Number	09/644,668			
Filing Date	August 24, 2000			
First Named Inventor	Alan J. Korman			
Art Unit	1644			
Examiner Name	J. H. Roark			
Attorney Docket Number	04280/100M321-US1			

42	CA-2,205,680-B1	11-16-1998	The University of Western Ontario	
43	EP-0 216 846-B2	04-26-1995	Celltech Limited	
44	EP-0 256 055-B1	08-28-1991	Celltech Limited	
45	EP-0 323 997 B1-B1	04-21-1993	Celltech Limited	
46	EP-0 338 841-B1	03-22-1995	Celltech Limited	
47	EP-0 463 151-B1	06-12-1996	Cell Genesys Inc.	
48	EP-0 546 073-B1	09-10-1997	GenPharm International, Inc.	
49	WO-WO 92/22647-A1	12-23-1992	GenPharm International, Inc.	
50	WO-WO 97/20574-A1	06-12-1997	The Regents of the University of California	
51	WO-WO 97/38137-A1	10-16-1997	Mercator Genetics, Inc.	
52	WO-WO 98/46996-A2	10-22-1998	The John P. Robarts Research Institute	
53	WO-WO 97/13852-A1	04-17-1997	GenPharm International, Inc.	
54	WO-WO 95/03408-A1	02-02-1995	Dana-Farber Cancer Institute	
55	WO-WO 98/50433-A2	11-12-1998	Abgenix, Inc.	
56	WO-WO 00/00569-A1	01-06-2000	National Silicates Ltd.	
57	WO-WO 96/14436-A1	05-17-1996	GenPharm International, Inc.	
58	WO-WO 96/22380-A2	07-25-1996	Cell Genesys, Inc.	
59	WO-WO 01/14424-A2	03-01-2001	Medarex, Inc.	
60	WO-WO 92/22670-A1	12-23-1992	GenPharm International, Inc.	
61	WO-WO 93/00431-A1	01-07-1993	Bristol-Myers Squibb Company	
62	WO-WO 95/01994-A1	01-19-1995	Synergen, Inc.	
63	WO-WO 95/24217-A1	09-14-1995	Dana-Farber Cancer Institute	
64	WO-WO 00/32231-A1	06-08-2000	The Regents of the University of California	
65	WO-WO 94/29444-A1	12-22-1994	The Government of the United States of America	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	66	L. Green et al.: "Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosome," J. Exp. Med., Volume 188, Number 3, August 3, 1998 483-495.				
	67	L. Green et al.: "Antigen-specific human monoconal antibodies from mice engineered with human Ig heavy and light chain YACs," Nature Genetics, Vol. 7, May 1994.				
	68	T. Choi et al.: "Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome," Nature Genetics, Vol. 4, June 1993.				
	69	N. Tuaillon et al.: "Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: Gene-segment use in μ and γ transcripts," Proc. Natl. Acad. Sci. USA., Vol. 99, pp.				

Examiner	Date	
Signature	Considered	



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
""				Application Number	09/644,668
l IN	IFORMATIO	N DI	SCLOSURE	Filing Date	August 24, 2000
l s	STATEMENT BY APPLICANT			First Named Inventor	Alan J. Korman
			-	Art Unit	1644
(Use as many sheets as necessary)		Examiner Name	J. H. Roark		
Sheet	3	of	3	Attorney Docket Number	04280/100M321-US1

	3720-3724, April 1993, Immunology.
70	N. Tuaillon et al.: "Analysis of Direct and Inverted DJ _h Rearrangements in a Human Ig Heavy Chain Transgenic Minilocus," The Journal of Immunology, 1995, 154: 6453-6465.
71	L. Taylor et al.: "Human immunoglobulin transgenes undergo rearrangment, somatic mutation and class switching in mice that lack endogenous IgM," International Immunology, Vol. 6, No. 4, pp. 579-591.
72	N. Lonberg et al.: "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," Nature, Vol. 368, 28 April 1994.
73	M. Mendez et al.: "Functional transplant ofmegabase human immunoglobullin loci recapitulates human antibody response in mice," Nature Genetics, Volume 15, February 1997.
74	L. Taylor et al.: "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins," Nucleic Acids Research, 1992, Vol. 20, No. 23, pp. 6287-6295.
75	J. Chen et al.: "Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the Jh locus," International Immunology, Vol. 5, No. 6, pp. 647-656.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.